Related Experiment Video
Updated: Aug 21, 2026

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety
Published on: November 11, 2022
[New molecular targets in pharmacological treatment of anxiety disorders]
Abstract:
Benzodiazepines are effective and widely used in anxiety disorders, but they produce sedation and dependency. Molecular studies have shown that binding benzodiazepines to GABAA receptors containing the Alpha1 subunit mediates the sedative properties of benzodiazepines. Other strategies are being developed including the use of the selective GABA reuptake inhibitor tiagabine and the voltage gated calcium ion channel ligand pregabalin. Several novel strategies are being developed based on preclinical observations, including corticotrophin-releasing factor (CRF) antagonists, substance P antagonists, and drugs inhibiting glutamate neurotransmission.
More Related Videos
Related Concept Videos
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drug Therapy
Antianxiety Medications
Anxiolytic Drugs: Benzodiazepines and Buspirone
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

